证券代码：688310 证券简称：迈得医疗 公告编号：2025-055 迈得医疗工业设备股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 110,857,696 | | 普通股股东所持有表决权数量 | 110,857,696 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 67.7502 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 67.7502 | 注：截至本次股东会股权登记日，公司回购专用账户中股份数为 2,592,575 股，不享有股东 会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、本次股东会所采用的表决方式是现场 ...

上海市锦天城律师事务所 法律意见书 关于迈得医疗工业设备股份有限公司 上海市锦天城律师事务所 2025 年第二次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 关于迈得医疗工业设备股份有限公司 2025 年第二次临时股东会的法律意见书 致：迈得医疗工业设备股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受迈得医疗工业设备股份 有限公司（以下简称"公司"）的委托，就公司召开 2025 年第二次临时股东会 （以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 等相关法律、法规和规范性文件以及《迈得医疗工业设备股份有限公司章程》（以 下简称"《公司章程》"）等内部规章制度的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定 ...

Group 1 - The core viewpoint of the news is that Maide Medical (688310) has seen a stock price increase of 2.04% to 15.47 yuan as of December 26, 2025, with a market capitalization of 2.571 billion yuan [1] - The highest intraday price recorded for Maide Medical on December 26 was 15.98 yuan, while the lowest was 14.81 yuan on December 24 [1] - Maide Medical ranks 74th out of 78 in the automation equipment sector by market capitalization and 4822nd out of 5178 in the overall A-share market [1] Group 2 - Maide Medical announced on December 11, 2025, that it would repurchase shares through centralized bidding [2] - As of December 19, 2025, the list of the top ten shareholders and the top ten unrestricted shareholders remained consistent [3] - Lin Junhua is the largest shareholder of Maide Medical, holding a 47.15% stake in the company [3]

Core Viewpoint - As of December 26, 2025, Maide Medical (688310) closed at 15.47 yuan, down 1.59%, with a turnover rate of 1.46% and a trading volume of 24,300 lots, amounting to 38.0012 million yuan in transaction value [1] Group 1: Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, an increase of 2.31% year-on-year [2] - The net profit attributable to shareholders was 8.8367 million yuan, up 15.82% year-on-year [2] - The non-recurring net profit was -1.2785 million yuan, a significant decrease of 526.58% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 83.643 million yuan, a year-on-year increase of 54.38% [2] - The single-quarter net profit attributable to shareholders was 2.7916 million yuan, up 224.07% year-on-year [2] - The single-quarter non-recurring net profit was 1.2364 million yuan, an increase of 118.23% year-on-year [2] - The company's debt ratio stood at 29.86%, with investment income of 167,600 yuan and financial expenses of -523,600 yuan, while the gross profit margin was 40.19% [2] Group 2: Business Overview - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, effectively integrating technology in medical device processes, automation, and software [2]

Core Viewpoint - The announcement from Maide Medical Industrial Equipment Co., Ltd. regarding the share buyback and the shareholding structure of its top shareholders indicates a strategic move to enhance shareholder value and reflects the company's current market position [1][2]. Group 1: Stock Performance - As of December 23, 2025, Maide Medical's stock closed at 15.11 yuan, down 0.07% from the previous trading day, with a total market capitalization of 2.512 billion yuan [1]. - The stock opened at 15.27 yuan, reached a high of 15.78 yuan, and a low of 15.04 yuan, with a trading volume of 43.5661 million yuan and a turnover rate of 1.72% [1]. Group 2: Share Buyback Announcement - The company held its eighth meeting of the fifth board of directors on December 11, 2025, where it approved a proposal to repurchase shares through centralized bidding [1]. - The announcement included the shareholding status of the top ten shareholders and the top ten unrestricted shareholders as of the registration date on December 19, 2025 [1]. Group 3: Shareholding Structure - Lin Junhua is the largest shareholder, holding 78,372,560 shares, which accounts for 47.15% of the total share capital [1]. - Chen Wanshun holds 24,754,800 shares, representing 14.89% of the total share capital [1]. - The remaining shareholders' ownership percentages decrease sequentially, with the lists of the top ten shareholders and the top ten unrestricted shareholders being identical [1].

Core Viewpoint - The company is in the early stages of commercializing its contact lens business, which has not yet significantly impacted overall performance [1] Group 1: Sales and Revenue - The company's online sales of contact lenses have not yet reached a million-level cumulative sales, and profitability and positive cash flow are not expected until 2026 [1] - As of the end of the third quarter, over 76 million units were shipped but not included in the third quarter revenue due to the shipping equipment not meeting the company's revenue recognition standards [1] Group 2: Inventory and Costs - The significant increase in inventory during the third quarter is primarily due to the order scheduling cycle, which resulted in higher costs being recorded in the inventory at the end of the third quarter [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-054 迈得医疗工业设备股份有限公司 关于回购股份事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、公司前十大无限售条件股东持股情况 | 序号 | 持有人名称 | 持股数量 | 占总股本比例 | | --- | --- | --- | --- | | | | （股） | （%） | | 1 | 林军华 | 78,372,560 | 47.15 | | 2 | 陈万顺 | 24,754,800 | 14.89 | | 3 | 台州赛纳投资咨询合伙企业（有限合伙） | 5,727,120 | 3.45 | | 4 | 迈得医疗工业设备股份有限公司回购专用证券 账户 | 2,592,575 | 1.56 | | 5 | 申万菱信基金－光大银行－申万菱信常鸿 号 1 集合资产管理计划 | 1,550,001 | 0.93 | | 6 | 王俏丽 | 1,263,082 | 0.76 | | 7 | 张鹏 | 1, ...

Group 1 - The core stock price of Maide Medical (688310) as of December 22, 2025, is 15.12 yuan, with a decrease of 0.26% and a turnover rate of 2.31% [1] - The net inflow of main funds on December 22 is 791.12 million yuan, accounting for 13.59% of the total transaction amount, while retail investors have a net outflow of 772.72 million yuan, accounting for 13.28% [1][2] Group 2 - Over the past five days, the stock has shown fluctuations, with a peak closing price of 15.16 yuan on December 19, 2025, reflecting a 2.57% increase [2] - The company reported a total revenue of 2.25 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 2.31%, while the net profit attributable to shareholders is 883.67 million yuan, up 15.82% year-on-year [3] - The third quarter of 2025 saw a significant increase in single-quarter revenue of 836.43 million yuan, up 54.38% year-on-year, and a net profit of 279.16 million yuan, up 224.07% year-on-year [3] Group 3 - Maide Medical's total market value is 2.513 billion yuan, with a net asset value of 840 million yuan, and a net profit of 8.8367 million yuan [3] - The company has a price-to-earnings ratio (P/E) of 213.31, which is significantly higher than the industry average of 132.02, indicating a relatively high valuation [3] - The gross profit margin stands at 40.19%, which is above the industry average of 27.79%, while the net profit margin is -2.43%, significantly lower than the industry average of 4.37% [3]

Core Viewpoint - Maide Medical (688310) is planning to repurchase shares to reduce its registered capital, with a total repurchase fund of 20 million to 40 million yuan, and a maximum repurchase price of 24 yuan per share [1] Group 1: Stock Performance - As of December 19, 2025, Maide Medical's stock closed at 15.16 yuan, up 2.57% from the previous trading day [1] - The stock opened at 14.72 yuan, reached a high of 15.2 yuan, and a low of 14.72 yuan, with a trading volume of 36.6862 million yuan and a turnover rate of 1.47% [1] Group 2: Share Repurchase Plan - The company intends to repurchase shares through centralized bidding, with the repurchase period set for 12 months from the date of approval by the shareholders' meeting [1] - The repurchased shares will be of the company's issued ordinary shares (A-shares), funded by either excess raised funds or self-owned funds [1] - The company will legally carry out the procedures for share cancellation and notify creditors, authorizing the board of directors and management to handle related matters [1]

二、公司前十大无限售条件股东持股情况 ■ 特此公告。 迈得医疗工业设备股份有限公司 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"）于2025年12月11日召开第五届董事会第八次会议， 审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。具体内容详见公司于2025年12月13 日披露在上海证券交易所网站（www.sse.com.cn）的《迈得医疗工业设备股份有限公司关于以集中竞价 交易方式回购股份的预案》（公告编号：2025-051）和《迈得医疗工业设备股份有限公司第五届董事会 第八次会议决议公告》（公告编号：2025-050）。 根据《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关规定，现将公司董事会公告 回购股份决议的前一个交易日（即2025年12月12日）登记在册的前十大股东和前十大无限售条件股东的 名称、持股数量和持股比例情况公告如下： 一、公司前十大股东持股情况 ■ 2025年12月19日 ...